Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma

被引：110

作者：

Abramson, Jeremy S. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Zero Emerson Pl, Boston, MA 02114 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

来源：

TRANSFUSION MEDICINE REVIEWS | 2020年 / 34卷 / 01期

关键词：

Diffuse large B-cell lymphoma; Non-Hodgkin lymphoma; Adoptive immunotherapy; CAR T-cells; Cell therapy; MARALEUCEL LISO-CEL; PATIENTS PTS; TRANSPLANTATION; RESPONSES; EFFICACY;

D O I：

10.1016/j.tmrv.2019.08.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CAR T-cells are autologous T-cells transduced with a chimeric antigen receptor which targets the modified T-cell against a specified cancer antigen. Anti-CD19 CAR T-cells currently represent transformational therapy for relapsed/refractory aggressive B-cell lymphomas where durable remissions can be induced in patients with previously incurable chemotherapy-refractory disease. Three anti-CD19 CAR T-cells are currently Food and Drug Administration and European Medicines Agency approved or in advanced-stage development: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Although all targeting CD19 on the surface of malignant (and healthy) B-cells, these products differ from one another in multiple ways including construct, manufacturing, dose, design of pivotal clinical trials, and toxicity profile. Efficacy and safety data for anti-CD19 CART-cell therapy in aggressive B-cell lymphomas will be reviewed, as well as novel CART-cell designs and strategies for overcoming treatment resistance. (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：29 / 33

页数：5

共 25 条

[1]

Abramson JS, 2019, ABELOFFS CLIN ONCOLO, P1926

[2] Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System [J].

Avanzi, Mauro P. ;

Yeku, Oladapo ;

Li, Xinghuo ;

Wijewarnasuriya, Dinali P. ;

van Leeuwen, Dayenne G. ;

Cheung, Kenneth ;

Park, Hyebin ;

Purdon, Terence J. ;

Daniyan, Anthony F. ;

Spitzer, Matthew H. ;

Brentjens, Renier J. .

CELL REPORTS, 2018, 23 (07) :2130-2141

[3] Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition [J].

Cherkassky, Leonid ;

Morello, Aurore ;

Villena-Vargas, Jonathan ;

Feng, Yang ;

Dimitrov, Dimiter S. ;

Jones, David R. ;

Sadelain, Michel ;

Adusumilli, Prasad S. .

JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) :3130-3144

[4] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[5] Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 [J].

Crump, Michael ;

Kuruvilla, John ;

Couban, Stephen ;

MacDonald, David A. ;

Kukreti, Vishal ;

Kouroukis, C. Tom ;

Rubinger, Morel ;

Buckstein, Rena ;

Imrie, Kevin R. ;

Federico, Massimo ;

Di Renzo, Nicola ;

Howson-Jan, Kang ;

Baetz, Tara ;

Kaizer, Leonard ;

Voralia, Michael ;

Olney, Harold J. ;

Turner, A. Robert ;

Sussman, Jonathan ;

Hay, Annette E. ;

Djurfeldt, Marina S. ;

Meyer, Ralph M. ;

Chen, Bingshu E. ;

Shepherd, Lois E. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) :3490-+

[6] Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection [J].

Eyquem, Justin ;

Mansilla-Soto, Jorge ;

Giavridis, Theodoros ;

van der Stegen, Sjoukje J. C. ;

Hamieh, Mohamad ;

Cunanan, Kristen M. ;

Odak, Ashlesha ;

Goenen, Mithat ;

Sadelain, Michel .

NATURE, 2017, 543 (7643) :113-+

[7] CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy [J].

Fry, Terry J. ;

Shah, Nirali N. ;

Orentas, Rimas J. ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance M. ;

Ramakrishna, Sneha ;

Wolters, Pamela ;

Martin, Staci ;

Delbrook, Cindy ;

Yates, Bonnie ;

Shalabi, Haneen ;

Fountaine, Thomas J. ;

Shern, Jack F. ;

Majzner, Robbie G. ;

Stroncek, David F. ;

Sabatino, Marianna ;

Feng, Yang ;

Dimitrov, Dimiter S. ;

Zhang, Ling ;

Sang Nguyen ;

Qin, Haiying ;

Dropulic, Boro ;

Lee, Daniel W. ;

Mackall, Crystal L. .

NATURE MEDICINE, 2018, 24 (01) :20-+

[8] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[9] IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo [J].

Koneru, Mythili ;

Purdon, Terence J. ;

Spriggs, David ;

Koneru, Susmith ;

Brentjens, Renier J. .

ONCOIMMUNOLOGY, 2015, 4 (03) :1-11

[10] Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses [J].

Kuramitsu, S. ;

Ohno, M. ;

Ohka, F. ;

Shiina, S. ;

Yamamichi, A. ;

Kato, A. ;

Tanahashi, K. ;

Motomura, K. ;

Kondo, G. ;

Kurimoto, M. ;

Senga, T. ;

Wakabayashi, T. ;

Natsume, A. .

CANCER GENE THERAPY, 2015, 22 (10) :487-495

← 1 2 3 →